



Novartis Oncology

# ASCO20 Virtual Scientific Program

Highlights of Accepted Novartis Data



## Breast Cancer

### Kisqali® (ribociclib)

#### Abstract # 1054 - Poster

May 29, 2020 | 8:00 am

Overall survival in patients with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib plus endocrine therapy in the MONALEESA-3 (ML-3) and -7 (ML-7) trials

---

#### Abstract # 1055 - Poster

May 29, 2020 | 8:00 am

Updated results from the Phase IIIb compLEEment-1 study of ribociclib plus letrozole in the treatment of HR+, HER2– ABC

---

#### Abstract # 1009 – Clinical Science Symposium

May 29, 2020 | 8:00 am

Pooled ctDNA analysis of the ML Phase III ABC trials

---

#### Abstract # e13048 – Publication Only

Real-world incidence, duration, and severity of treatment-emergent neutropenia among patients with metastatic breast cancer (mBC) treated with ribociclib or palbociclib

---

#### Abstract # e13037 – Publication Only

Integrative assessment of the effect of renal function on ribociclib treatment and dose recommendation in ABC patients

---

## Piqray® (alpelisib)

#### Abstract # 1006 - Oral

May 29, 2020 | 8:00 am

Alpelisib + fulvestrant in patients with *PIK3CA*-mutated HR+/*HER2*– ABC previously treated with cyclin-dependent kinase inhibitor (CDKi) + aromatase inhibitor: BYLieve study results



## Melanoma

### Tafinlar® + Mekinist® (dabrafenib + trametinib) ± spartalizumab (PDR001)

#### Abstract # 10001 - Oral

May 29, 2020 | 8:00 am

Long-term benefit of adjuvant dabrafenib + trametinib in patients with resected stage III BRAF V600-mutant melanoma: five-year analysis of COMBI-AD

---

#### Abstract # 10028 - Poster

May 29, 2020 | 8:00 am

The anti-PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600-mutant melanoma: efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial

---

#### Abstract # 10034 - Poster

May 29, 2020 | 8:00 am

Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients with advanced BRAF V600-mutant melanoma

---

## Lung Cancer

### Tabrecta™ (capmatinib)

#### Abstract # 9509 - Oral

May 29, 2020 | 8:00 am

Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the Phase II GEOMETRY mono-1 study

---

#### Abstract # 9520 – Poster Discussion

May 29, 2020 | 8:00 am

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced NSCLC: results from cohort 6 of the Phase II GEOMETRY mono-1 study



## Canakinumab (ACZ885)

### Abstract # TPS9626 - Poster

May 29, 2020 | 8:00 am

CANOPY-N: a Phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in patients with surgically resected (stage IB-IIIa) NSCLC

---

### Abstract # TPS9075 - Poster

May 29, 2020 | 8:00 am

CANOPY-A: a Phase III, multicenter, randomized trial evaluating canakinumab versus placebo as adjuvant therapy in patients with completely resected NSCLC

---

## Neuroendocrine Tumors

### Lutathera® (<sup>177</sup>Lu-DOTATATE)

### Abstract # 4604 - Poster

May 29, 2020 | 8:00 am

Safety of <sup>177</sup>Lu DOTATATE in patients with advanced neuroendocrine tumors: data from a US expanded access program

---

## General Oncology

### Patient Engagement

### Abstract # e14084 – Publication Only

Patient engagement in clinical trial design and implementation: A pragmatic approach to valued insights



# Febrile Neutropenia

## Filgrastim-sndz

### **Abstract # e19401 – Publication Only**

Cost-effectiveness of filgrastim-sndz as primary prophylaxis vs. secondary prophylaxis to prevent chemotherapy-induced febrile neutropenia (FN) in NSCLC patients at intermediate risk

---

### **Abstract # e24116 – Publication Only**

Real-world myeloid growth factor prophylaxis patterns in patients receiving chemotherapy at intermediate risk for FN: a systematic review